Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 9, 2021

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with CKD.